Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80

Latest First-Time Offerings Bring In $1.2bn

Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering. 

Finance Watch Public Company

Ten biopharmaceutical companies launched initial public offerings in the US during the last week of July, raising $1.2bn combined, bringing last month’s total to 18 IPOs. Added to the 62 first-time offerings during the first half of 2021, 80 drug developer have gone public so far this year, which means the industry is just six IPOs away from matching the record-breaking 2020 total of 86 IPOs.

More from Financing

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By 

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By 

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

More from Business

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By 

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Will They Or Won’t They? Tariff Question Looms For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.